No improvement of posttraumatic stress disorder symptoms with guanfacine treatment

Am J Psychiatry. 2006 Dec;163(12):2186-8. doi: 10.1176/appi.ajp.163.12.2186.

Abstract

Objective: The authors report an 8-week, double-blind, randomized controlled trial of guanfacine versus placebo for posttraumatic stress disorder (PTSD).

Method: Veterans with chronic PTSD who were medication-free or receiving stable pharmacotherapy were randomly assigned to guanfacine (N=29) versus placebo (N=34).

Results: Guanfacine had no effect on PTSD symptoms, subjective sleep quality, or general mood disturbances. Guanfacine was associated with a number of side effects.

Conclusions: These results do not support the use of alpha 2 agonists in veterans with chronic PTSD.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Adrenergic alpha-Agonists / adverse effects
  • Adrenergic alpha-Agonists / therapeutic use*
  • Chronic Disease
  • Comorbidity
  • Double-Blind Method
  • Guanfacine / adverse effects
  • Guanfacine / therapeutic use*
  • Humans
  • Mood Disorders / drug therapy
  • Mood Disorders / epidemiology
  • Mood Disorders / psychology
  • Placebos
  • Sleep / drug effects
  • Stress Disorders, Post-Traumatic / drug therapy*
  • Stress Disorders, Post-Traumatic / epidemiology
  • Stress Disorders, Post-Traumatic / psychology
  • Treatment Outcome
  • Veterans / psychology

Substances

  • Adrenergic alpha-Agonists
  • Placebos
  • Guanfacine